If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
=== Use in poultry industries === Broiler chickens are yellow when they are fed with carotenoid-containing feed, as these carotenoids accumulate in the skin and subcutaneous fat of the animal. Carotenoid deposition is also the cause of the yellow colour of egg yolk. For this reason, poultry producers add carotenoids (typically lutein, zeaxanthin, canthaxanthin, and β-apo-8´-apocarotenal) to the feed to increase the attractiveness of the final product for the consumer, but also to support animal health. It is believed that lutein and zeaxanthin act synergistically to increase the yellow hue, whereas zeaxanthin is more powerful than lutein due to its larger chromophore. Therefore, several companies use marigold extract where a percentage of lutein has been converted into meso-zeaxanthin in order to supplement broilers and hens with both carotenoids. The isomer of zeaxanthin obtained from lutein is meso-zeaxanthin due to the nature of the technique used (see below).
== Function == Vitellogenin provides the major egg yolk protein that is a source of nutrients during early development of egg-laying (oviparous) vertebrates and invertebrates. Although vitellogenin also carries some lipid for deposition in the yolk, the primary mechanism for deposition of yolk lipid is instead via VLDLs, at least in birds and reptiles. Vitellogenin precursors are multi-domain apolipoproteins (proteins that bind to lipids to form lipoproteins), that are cleaved into distinct yolk proteins. Different vitellogenin proteins exist, which are composed of variable combinations of yolk protein components; however, the cleavage sites are conserved.
== Rivalries == The club's fans share a fierce and often violent rivalry with the supporters of Chemie Leipzig. When both teams met in the quarter finals of the Sachsenpokal in 2016, German daily newspaper Die Welt called the match the "German hooligan summit". An additional reason for the enmity between some fan groups (namely their ultras) is a political one. Whereas certain Chemie fan clubs express left-wing and anti-fascist political views, Lok has vocal supporters from the right and far-right of the political spectrum. Lok also have lesser local rivalry with RB Leipzig.
Sources: en.wikipedia.org
After the wound debridement, adequate dressings should be applied to promote wound healing. Wounds are generally packed with wet-to-dry dressings and left open to heal. In certain cases, vacuum-sealing drainage (VSD) may help the wound heal, especially in Fournier gangrene. For necrotizing infection of the perineal area (Fournier's gangrene), wound debridement and care in this area can be difficult because of the excretory products that often render the area dirty and negatively affect wound healing. Therefore, regular dressing changes with a fecal management system can help to keep the wound in the perineal area clean. Sometimes, colostomy may be necessary to divert the excretory products to keep the wound in the perineal area clean.
== Product life cycle approach in validation == Validation process efforts must account for the complete product life cycle, including developmental procedures adapted for qualification of a drug product commencing with its research and development phase, rationale for adapting a best fit formula which represents the relationship between required outputs and specified inputs, and procedure for manufacturing. Each step is required to be justified and monitored in order to provide a good quality food and drug product. The FDA emphasizes the product life cycle approach in its evaluation of manufacturer regulatory compliance as well.
Growing from a taproot like a carrot, dill grows up to 0.5–1.5 metres (1+1⁄2–5 feet) tall. Its stems are slender and hollow with finely divided, softly delicate leaves; the leaves are alternately arranged, 10–20 centimetres (4–8 inches) long with ultimate leaf divisions measuring 1–2 millimetres (1⁄32–3⁄32 in) broad, slightly wider than the similar leaves of fennel, which are less than 1 mm (1⁄16 in) across but harder in texture. In hot or dry weather, small white to yellow scented flowers form in small umbels 2.5–9 cm (1–3+1⁄2 in) in diameter from one long stalk. The seeds come from dried up fruit 4–5 mm (3⁄16–3⁄16 in) long and 1 mm (1⁄16 in) thick, and straight to slightly curved with a longitudinally ridged surface.
Sources: en.wikipedia.org
South Africa and Portugal, Rhodesia's largest trading partners, also refused to extend diplomatic recognition, and did not open embassies in the Rhodesian capital, Salisbury, preferring to conduct diplomatic activities through "accredited representatives". This allowed the South African and Portuguese governments to maintain they were continuing to respect British sovereignty while also accepting the practical authority of the Smith administration. Initially, the Rhodesian state retained its pledged loyalty to Queen Elizabeth II, recognising her as Queen of Rhodesia. When Smith and Deputy Prime Minister Clifford Dupont visited Sir Humphrey Gibbs, the Governor of Southern Rhodesia, to formally notify him of the UDI, Gibbs condemned it as an act of treason. After Smith formally announced the UDI on the radio, Governor Gibbs used his reserve power to dismiss Smith and his entire cabinet from office, on orders from the Colonial Office in Whitehall. However, Gibbs was unable to take any concrete actions to bring about a return to lawful colonial government. Rhodesian ministers simply ignored his notices, contending that UDI had made his office obsolete. Even so, Gibbs continued to occupy his official residence, Government House, in Salisbury until 1970, when he finally left Rhodesia, following the declaration of a republic. He had effectively been superseded before then; the Smith government stated that if the Queen did not appoint a Governor-General, it would name Dupont as "Officer Administering the Government".
==== Oral isotretinoin ==== Oral isotretinoin (retinoic acid isomer) is recommended for treating treatment resistant acne, acne that can lead to scarring, and acne that is associated with psychosocial distress. It is approved by the FDA for treating severe acne vulgaris that is resistant to other treatment options. Isotretinoin is a known teratogen, with an estimated 20–35% risk of physical birth defects to infants that are exposed to isotretinoin in utero, including numerous congenital defects such as craniofacial defects, cardiovascular and neurological malformations or thymic disorders. Neurocognitive impairments in the absence of any physical defects has been established to be 30–60%. For these reasons, physician- and patient-education programs were initiated, recommending that for women of child-bearing age, contraception be initiated a month before starting oral (or topical) isotretinoin, and continue for a month after treatment ended. In the US, isotretinoin was released to the market in 1982 as a revolutionary treatment for severe and refractory acne vulgaris. It was shown that a dose of 0.5–1.0 mg/kg body weight/day is enough to produce a reduction in sebum excretion by 90% within a month or two, but the recommended treatment duration is 4 to 6 months. The mechanism by which orally consumed retinoic acid (RA), as all-trans-tretinoin or 13-cis-isotretinoin improves facial skin health is thought to be by switching on genes and differentiating keratinocytes (immature skin cells) into mature epidermal cells.
== Nomenclature == This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-2-aminoadipate-6-semialdehyde:NAD(P)+ 6-oxidoreductase. Other names in common use include:
==== Oily skin ==== Oily skin is caused by over-active sebaceous glands, that produce a substance called sebum, a naturally healthy skin lubricant. A high glycemic-index diet and dairy products (except for cheese) consumption increase IGF-1 generation, which in turn increases sebum production. Overwashing the skin does not cause sebum overproduction but may cause dryness. When the skin produces excessive sebum, it becomes heavy and thick in texture, known as oily skin. Oily skin is typified by shininess, blemishes and pimples. The oily-skin type is not necessarily bad, since such skin is less prone to wrinkling, or other signs of ageing, because the oil helps to keep needed moisture locked into the epidermis (outermost layer of skin). The negative aspect of the oily-skin type is that oily complexions are especially susceptible to clogged pores, blackheads, and buildup of dead skin cells on the surface of the skin. Oily skin can be sallow and rough in texture and tends to have large, clearly visible pores everywhere, except around the eyes and neck.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.